Blood-flow metabolism mismatch predicts pancreatic tumor aggressiveness

Based on these findings, they suggested that the relationship between several physiological tumor parameters might provide more important information about a tumor than just looking at any of these parameters alone.

Gaber Komar, M.D., research fellow at the Turku PET Center, and colleagues investigated the importance of two physiological parameters in the tumor microenvironment among patients with pancreatic tumors to evaluate tumor aggressiveness. The parameters measured were blood flow in the tumor tissue and glucose consumption, which could be seen as a measurement of general metabolic activity of a tissue.

"Imaging of several of these tumor parameters might be important for the planning and success of oncologic therapies," Komar said. "We believe that a better understanding of these mechanisms may help overcome the general treatment resistance of pancreatic cancer."

The researchers used positron emission tomography (PET), a nuclear medicine imaging technique that provides a three-dimensional image of a bodily process, to measure blood flow and glucose consumption in 26 patients with pancreatic cancer. A PET scan is most often used to detect cancer and is also used to evaluate cancer response. It is emerging as a tool for pre-therapy evaluation of tumors and allows researchers to study and quantify tumor characteristics while the tumor is still in the body.

Results showed that patients with benign (n=8) and malignant (n=11) tumors had decreased blood flow of the lesion by 48 percent and 60 percent compared to patients with normal pancreatic tissue (n=7). These findings may help explain the lack of success some patients experience with radiotherapy and chemotherapy, the researchers suggested.

Komar said he was somewhat surprised by the results of the study since they did not expect to see such a clear correlation in such a small sample size.

"The important new step in the future might be the integration of these findings in management of a single tumor and combination of this information with the appropriate therapeutic approach including early monitoring of tumor responsiveness," Komar said.

David Mankoff, M.D., Ph.D., professor of radiology, medicine and bioengineering at the University of Washington and an academic physician at the Seattle Cancer Care Alliance, said this is the latest finding in a series of studies that have shown that a blood-flow metabolism mismatch in tumor is a sign of a resistant tumor and a predictor of bad outcome.

"This study confirms that blood flow metabolism mismatch exists in pancreatic tumors, similar to other cancers such as breast and lung cancers, and predicts poor patient outcome," said Mankoff. "A blood-flow metabolism mismatch by PET appears to be associated with cancer aggressiveness and treatment resistance. We've only recently recognized this pattern as a result of advantages in functional imaging methods."

Mankoff, who is also an editorial board member for the AACR's journal Clinical Cancer Research, said he believes this study has a few implications. As researchers begin to use new methods, such as PET imaging to explore in vivo biology, they may uncover factors that point towards behavior that is more aggressive and suggests new avenues for treatment, therefore leading to better patient outcome. For example, Mankoff said that the findings identified by Komar and colleagues may lead researchers to study the role that tumor tissue oxygenation and hypoxia play in mediating tumor clinical behavior and responsiveness to systemic therapy.

Source: American Association for Cancer Research (news : web)